Recipharm has announced the acquisition of GenIbet, a Portuguese CDMO, specializing in the manufacture of biological clinical trial material and novel modalities such as viral vectors, RNA and microbiome.
The acquisition forms part of Recipharm’s strategy to grow in the biologics market, with a particular focus on drug substance manufacturing of novel ATMPs, the company states.
“We’re delighted to welcome GenIbet and its talented team of experts. GenIbet is a leading player in its field so we’re proud to bring it under the Recipharm umbrella and tap into its broad offering in novel modalities and incredible scientific expertise. This acquisition is an important step for us in growing our biologics business. We look forward to working closely with the GenIbet team, building links across the wider Recipharm organisation to make this business a huge success,” says Marc Funk, Chief Executive Officer at Recipharm.
GenIbet currently works with customer projects in the preclinical and Phase 1 stages and has a track record of developing novel production processes. Through its relationship with not-for-profit research organisation Ibet, the CDMO offers deep scientific expertise and novel solutions where no established production route exists.
GenIbet was founded as a spin-off of Ibet – Instituto de Biologia Experimental e Tecnológica – in 2006 and currently has around 70 employees. Its Portuguese facility is located in Oeiras, just 11 km from Recipharm’s facility in Lisbon.
Photo of Marc Funk: Recipharm